Neogen Corporation Common Stock (NEOG)
Stock · NASDAQ · Health Care
$11.82as of 10/16/2026
Price chart
Active signals
NEOG Signal Track Record
How signals performed across all stocks →What NEOG's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | -2.1% | 46% | September 28, 2026 |
| Bollinger Band Breakdown | 23 | -2.1% | 43% | May 11, 2026 |
| Bollinger Band Breakout | 22 | +1.8% | 55% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -2.7% | 15% | November 11, 2025 |
| Any 20-session window (baseline) | -1.2% | 47% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NEOG
Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. The company offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural to…
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Employees
- 2,636
- Website
- www.neogen.com/
Fundamentals
- 1-day range
- $11.85$12.35
- Market cap
- $2.46B
- P/E (trailing)
- —
- P/E (forward)
- 30.42
- EPS (trailing)
- $-0.26
- Dividend yield
- —
- Beta
- 1.88
- Avg. volume
- 3.24M
How Neogen Corporation Common Stock Makes Money
Where the revenue actually goes — FY2026 annual results
Source: 10-K filed Jul 30, 2026 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
Neogen Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- NEOGNeogen Corporation Common Stock$11.81▼ 3.75%Market cap $2.46BP/E —$5.37$14.26
- CLDXCelldex Therapeutics Inc.$27.53▼ 4.84%Market cap $3.26BP/E —$22.1$45.14
- NTLAIntellia Therapeutics Inc. Common Stock$11.42▲ 0.71%Market cap $1.57BP/E —$7.95$28.25
- NNNNAnbio Biotechnology Class A Ordinary Shares$3.13▼ 5.15%Market cap $1.40BP/E 46.55$3.52$44.73
- QDELQuidelOrtho Corporation Common Stock$12.91▼ 7.19%Market cap $1.11BP/E —$9.92$35.58
- ACHVAchieve Life Sciences Inc. Common Shares$6.38▼ 8.46%Market cap $672.42MP/E —$2.62$8.64
- TKNOAlpha Teknova Inc. Common Stock$7.08▼ 6.84%Market cap $350.10MP/E —$1.91$9.48
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NEOG Neogen Corporation Common Stock | $2.46B | — | $11.81 | ▼ 3.75% | $5.37$14.26 |
| CLDX Celldex Therapeutics Inc. | $3.26B | — | $27.53 | ▼ 4.84% | $22.1$45.14 |
| NTLA Intellia Therapeutics Inc. Common Stock | $1.57B | — | $11.42 | ▲ 0.71% | $7.95$28.25 |
| NNNN Anbio Biotechnology Class A Ordinary Shares | $1.40B | 46.55 | $3.13 | ▼ 5.15% | $3.52$44.73 |
| QDEL QuidelOrtho Corporation Common Stock | $1.11B | — | $12.91 | ▼ 7.19% | $9.92$35.58 |
| ACHV Achieve Life Sciences Inc. Common Shares | $672.42M | — | $6.38 | ▼ 8.46% | $2.62$8.64 |
| TKNO Alpha Teknova Inc. Common Stock | $350.10M | — | $7.08 | ▼ 6.84% | $1.91$9.48 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Neogen Corporation 2027 Q1 - Results - Earnings Call PresentationSeekingAlpha · 10/10/2026
- 3 Medical Product Stocks Positioned to Ride on the Industry TailwindsYahoo · 10/9/2026
- Neogen (NEOG) Received An FDA Warning Over Contaminated Veterinary ProductYahoo · 10/8/2026
- Why Is Neogen Stock Gaining Thursday?benzinga · 10/8/2026
- Why Is Neogen Stock Gaining Thursday?Benzinga · 10/8/2026
- Neogen Corporation: Promising Recurring Demand With Food SafetySeekingAlpha · 10/8/2026
- The 5 Most Interesting Analyst Questions From Neogen’s Q3 Earnings CallYahoo · 10/8/2026
- Neogen Corporation (NEOG) Analyst/Investor Day - SlideshowSeekingAlpha · 10/8/2026
- Neogen Investor Day Sets Path for Growth, 30% EBITDA Margin by 2031Yahoo · 10/8/2026
Insider Activity
Insider Actions →- Nassif Mikheal · October 9, 2026 · Buy505 @ $11.95
- CAPELLO JEFFREY D · October 1, 2026 · Grant9.8K @ $12.24
- RODRIGUEZ RAFAEL A · October 1, 2026 · Grant20.6K
- Aashima Gupta · October 1, 2026 · Grant20.6K
- Aashima Gupta · October 1, 2026 · Grant9.8K @ $12.24
- Woteki Catherine E · October 1, 2026 · Grant20.6K
- Woteki Catherine E · October 1, 2026 · Grant9.8K @ $12.24
- Andrea F. Wainer · October 1, 2026 · Grant20.6K
- Andrea F. Wainer · October 1, 2026 · Grant9.8K @ $12.24
- Green Ronald D · October 1, 2026 · Grant20.6K
- Green Ronald D · October 1, 2026 · Grant9.8K @ $12.24
- Pelossof Avi · October 1, 2026 · Grant20.6K
- Pelossof Avi · October 1, 2026 · Grant9.8K @ $12.24
- BOREL JAMES C · October 1, 2026 · Grant20.6K
- BOREL JAMES C · October 1, 2026 · Grant9.8K @ $12.24
Institutional Ownership
March 31, 2026
- Total shares held
- 221.26M
- Total value held
- $1.87B
- Institutional holders
- 303
- Unknown32.62M
- Unknown10.16M
- Unknown9.57M
- Unknown9.13M
- Unknown8.90M
- Unknown8.59M
- Unknown7.80M
- Unknown7.75M
- Unknown6.50M
- Unknown6.27M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Neogen Corp reports earnings, faces FDA warning, outlines growth plan
Neogen released its 2027 Q1 earnings presentation, highlighting recent revenue trends and upcoming initiatives. The company also disclosed an FDA warning related to a contaminated veterinary product, which may affect short‑term perception. At its recent Investor Day, management outlined a plan to reach a 30% EBITDA margin by 2031 and emphasized growing demand for food‑safety solutions. Analysts continue to note the stock’s recent price movement amid these developments.
Neogen Corp reports earnings, faces FDA warning, outlines growth plan. Neogen released its 2027 Q1 earnings presentation, highlighting recent revenue trends and upcoming initiatives. The company also disclosed an FDA warning related to a contaminated veterinary product, which may affect short‑term perception. At its recent Investor Day, management outlined a plan to reach a 30% EBITDA margin by 2031 and emphasized growing demand for food‑safety solutions. Analysts continue to note the stock’s recent price movement amid these developments.